Construction of a phage displayed library based on a lipocalin scaffold and preliminary screening of anticalins with specificity for the FcεRI-α receptor

doi:10.5246/jcps.2019.11.073

Abstract

Abstract:

The primers were designed according to the gene sequence of lipocalin protein family, and the gene sequence containing random mutation protein was obtained by overlapping extension of PCR. The random mutation lipocalin library was constructed using phagemid expression vector. Lipocalin library was screened by subtracted screening of NSF60 cells and affinity screening of mast cells, and the lipocalin secondary library binding to mast cells was obtained. Then the lipocalin secondary library was enriched and screened with FcεRI-α receptor protein as target molecule, and specific binding phages were eluted. After three rounds of screening, eight recombinant phage clones were randomly selected from elution clones of the third round. ELISA assay showed that three anticalin molecules could specifically bind to the FcεRI-α receptor of mast cells. These results may provide some candidate biological molecules for the development of blocking drugs of mast cell FcεRI-α receptor, and also lay the foundation for the development of biological small molecule drugs to treat IgE associated allergic diseases.

Key words: Lipocalin, FcεRI-&alpha, receptor, Anticalin molecules, Phage display, Mast cell

CLC Number:

R966

Supporting:

Hua Peng, Jinkui Ma, Jie Cheng, Chengzhi Huang, Hongbin Zhang. Construction of a phage displayed library based on a lipocalin scaffold and preliminary screening of anticalins with specificity for the FcεRI-α receptor[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(11): 770-777.

References

[1] Soto-Martínez, M.E.; Yock-Corrales, A.; Camacho-Badilla, K.; Abdallah, S.; Duggan, N.; Avila-Benedictis, L.; Romero, J.J.; Soto-Quirós, M.E. The current prevalence of asthma, allergic rhinitis, and eczema related symptoms in school-aged children in Costa Rica. J. Asthma. 2019, 56, 360-368.

[2] Brożek, J.L.; Bousquet, J.; Agache, I.; Agarwal, A.; Bachert, C.; Bosnic-Anticevich, S.; Brignardello-Petersen, R.; Canonica, G.W.; Casale, T.; Chavannes, N.H.; Correia de Sousa, J.; Cruz, A.A.; Cuello-Garcia, C.A.; Demoly, P.; Dykewicz, M.; Etxeandia-Ikobaltzeta, I.; Florez, I.D.; Fokkens, W.; Fonseca, J.; Hellings, P.W.; Klimek, L.; Kowalski, S.; Kuna, P.; Laisaar, K.T.; Larenas-Linnemann, D.E.; Lødrup Carlsen, K.C.; Manning, P.J.; Meltzer, E.; Mullol, J.; Muraro, A.; O'Hehir, R.; Ohta, K.; Panzner, P.; Papadopoulos, N.; Park, H.S.; Passalacqua, G.; Pawankar, R.; Price, D.; Riva, J.J.; Roldán, Y.; Ryan, D.; Sadeghirad, B.; Samolinski, B.; Schmid-Grendelmeier, P.; Sheikh, A.; Togias, A.; Valero, A.; Valiulis, A.; Valovirta, E.; Ventresca, M.; Wallace, D.; Waserman, S.; Wickman, M.; Wiercioch, W.; Yepes-Nuñez, J.J.; Zhang, L.; Zhang, Y.; Zidarn, M.; Zuberbier, T.; Schünemann, H.J. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2016 revision. J. Allergy Clin. Immunol. 2017, 140, 950-958.

[3] Devereux, G. The increase in the prevalence of asthma and allergy: food for thought. Nat. Rev. Immunol. 2006, 6, 869-874.

[5] Schlehuber, S.; Beste, G.; Skerra, A. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J. Mol. Biol. 2000, 297, 1105-1120.

[6] Mercader, J.V.; Skerra, A. Generation of anticalins with specificity for a nonsymmetric phthalic acid ester. Anal. Biochem. 2002, 308, 269-277.

[7] Wu, J.; Yang, J.Y.; Zhang, H.B.; Pan, K.; Wang, H.; Lei, H.T.; Zheng, L.; Xiao, Z.L.; Sun, Y.M. Construction of phage-displayed library based on the lipocalin scaffold and screening anticalins with specificity for carbofuran. Chem. J. Chin. Univ. 2008, 29, 528-532.

[8] Schiefner, A.; Skerra, A. The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds. Acc. Chem. Res. 2015, 48, 976-985.

[9] Richter, A.; Eggenstein, E.; Skerra, A. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett. 2014, 588, 213-218.

[10] Breustedt, D.A.; Schönfeld, D.L.; Skerra, A. Comparative ligand-binding analysis of ten human lipocalins. Biochim. Biophys. Acta. 2006, 1764, 161-173.

[11] Schmidt, F.S.; Skerra, A. The bilin-binding protein of Pieris brassicae. cDNA sequence and regulation of expression reveal distinct features of this insect pigment protein. Eur. J. Biochem. 1994, 219, 855-863.

[12] Vogt, M.; Skerra, A. Construction of an artificial receptor protein (“anticalin”) based on the human apolipoprotein D. ChemBioChem. 2004, 5, 191-199.

[13] Breustedt, D.A.; Chatwell, L.; Skerra, A. A new crystal form of human tear lipocalin reveals high flexibility in the loop region and induced fit in the ligand cavity. Acta Crystallogr. D Biol. Crystallogr. 2009, 65, 1118-1125.

[14] Borregaard, N.; Cowland, J.B. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals. 2006, 19, 211-215.

[15] Beste, G.; Schmidt, F.S.; Stibora, T.; Skerra, A. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc. Natl. Acad. Sci. USA. 1999, 96, 1898-1903.

[16] Vopel, S.; Mühlbach, H.; Skerra, A. Rational engineering of a fluorescein-binding anticalin for improved ligand affinity. Biol. Chem. 2005, 386, 1097-1104.

[17] Liu, J.Q.; Ning, B.A.; Liu, M.; Sun, Y.N.; Sun, Z.Y.; Zhang, Y.H.; Fan, X.J.; Zhou, Z.J.; Gao, Z.X. Construction of ribosome display library based on lipocalin scaffold and screening anticalins with specificity for estradiol. Analyst. 2012, 137, 2470-2479.

[18] Albrecht, V.; Richter, A.; Pfeiffer, S.; Gebauer, M.; Lindner, S.; Gieser, E.; Schüller, U.; Schichor, C.; Gildehaus, F.J.; Bartenstein, P.; Tonn, J.C.; Skerra, A.; Glass, R. Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas. Int. J. Cancer. 2016, 138, 1269-1280.

[19] Smith, L.D.; Leatherbarrow, R.J.; Spivey, A.C. Development of small molecules to target the IgE: FcεRI protein-protein interaction in allergies. Future Med. Chem. 2013, 5, 1423-1435.

[20] Qiao, C.X.; Lv, M.; Guo, L.M.; Yu, M.; Li, Y.; Lin, Z.; Hua, X.L.; Hou, C.M.; Feng, J.N.; Shen, B.F. Inhibition of IgE activity to bind its high affinity receptor (FcεRIα) by mouse anti-IgE cε3∼4 monoclonal antibody (QME5). Int. J. Biomed. Sci. 2009, 5, 336-344.

[21] Stokes, J. Anti-IgE treatment for disorders other than asthma. Front Med. (Lausanne). 2017, 4, 152.

[22] Hashiguchi, S.; Nakashima, T.; Nitani, A.; Yoshihara, T.; Yoshinaga, K.; Ito, Y.; Maeda, Y.; Sugimura, K. Human Fc epsilon RIalpha-specific human single-chain Fv (scFv) antibody with antagonistic activity toward IgE/Fc epsilon RIalpha-binding. J. Biochem. 2003, 133, 43-49.

[1]	Ning Ma, Chao Ji. Acetylcholine ameliorates inflammatory microenvironment via regulating the balance of IL-1β/IL-1RA [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 260-267.
[2]	Yingzheng Wang, Ce Yang, Cuiping Zhu, Qianqian Zhao, Xuehua Lu, Xiaoyu Su, Yinghao Wang. Upper limb arthromyodynia can be treated with Notopterygium by down-regulating P2X3 to mediate PKC-induced inflammatory response [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(3): 163-175.
[3]	Jingting Kang, Chao Ji. The mechanism of galanthamine regulating IL-1β/IL-1RA ratio to ameliorate inflammatory microenvironment [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(10): 773-781.
[4]	Ling Yong, Ye Yao, Mengyi Han, Xiaoxue Yan, Qingyu Yao, Yuchen Guo, Junsheng Xue, Guoshu Chen, Tianyan Zhou. QAP21 reduces stemness and mobility of metastatic breast cancer cells involving D1DR activation [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 289-305.
[5]	Shaohong Luo, Liangliang Dong, Yiyuan Li, Dan Xu, Min Chen. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(3): 253-263.
[6]	Chuhang Zhou, Xinping Hu, Qi Liu, Leqi Wang, Yuanhang Zhou, Yao Jin, Yan Liu. Enhanced tumor-targeted delivery of anticancer drugs by folic acid-conjugated pH-sensitive polymeric micelles [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(9): 626-636.
[7]	Yuqi Xie, Yushun Dou, Yue Tang. Intranasal delivery of rapid-onset antidepressants: a new trend of treating major depressive disorder [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 515-527.
[8]	Xiao Cheng, Yinglin Yang, Weihan Li, Man Liu, Shanshan Zhang, Yuehua Wang, Guanhua Du. Esculin alleviates acute kidney injury and inflammation induced by LPS in mice and its possible mechanism [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(5): 322-332.
[9]	Shuxiang Song. The research group of Pengfei Tu and Yong Jiang created the efficient discovery of a precise microfluidic assay in single-cell technique for Transient Receptor Potential Channel regulator [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(5): 372-373.
[10]	Meng Lei, Xueyuan Wang, Hang Miao, Jia Wang, Sijia Sha, Jiang Zhu, Yongqiang Zhu. Co-delivery of paclitaxel and gemcitabine via folic acid-conjugated polymeric multi-drug nanoparticles (FA-PMDNPs) for the treatment of breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 701-710.
[11]	Liang Yang, Ye Yao, Yaoyao Feng, Wei Lu, Tianyan Zhou. Pharmacodynamic model of dopamine D1 receptor agonists in the treatment of breast cancer lung metastasis [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(1): 45-54.
[12]	Ning Li, Yingying Liang, Qi Sun, Yimin Jiang, Runtao Li, Jia Ye. The spirocyclopiperazinium salt compound LXM-15 alleviates chronic inflammatory and neuropathic pain in mice and rats [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(6): 371-380.
[13]	Xiao Cheng, Huan Yang, Yinglin Yang, Weihan Li, Man Liu, Yuehua Wang, Guanhua Du. Xiao-Xu-Ming decoction extract alleviates LPS-induced neuroinflammation associated with down-regulating TLR4/MyD88 signaling pathway in vitro and in vivo [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(2): 88-99.
[14]	Yaoyao Feng, Peili Jiao, Xiaoxue Yan, Zixi Xue, Ye Yao, Liang Yang, Daming Kong, Hong Su, Ling Yong, Guoshu Chen, Tianyan Zhou. Compound C17 inhibits the lung metastasis of breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(10): 716-727.
[15]	Jian Xin, Xiangnan Xu, Yuping Wang, Zhentao Zhang, Yuheng Ma. The development and application of peroxisome proliferator-activated receptor (PPAR) modulator [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(4): 215-228.